Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 10, 2012

Pathway, Scripps Get Personal with Genes

  • Scripps Center for Executive Health and Pathway Genomics have agreed a partnership that will allow the Scripps center to offer elements of Pathway’s suite of genetic tests to patients through Scripps Health physicians, clinics, hospitals and healthcare organizations.

    Pathway operates as a CLIA-certified clinical genetic testing laboratory that offers a suite of tests including carrier status for recessive genetic conditions, prescription drug response, food, nutrition, and exercise responses, and risk of developing disorders such as heart disease, type 2 diabetes, and cancer. Genetic testing and analyses on a patient’s saliva sample will be carried out by Pathway, and the results will be incorporated into a customized long-term heath strategy provided by the Scripps center.

    In July Pathway launched its newest genetic testing service, the Cardiac Health Insight, which is designed to provide an indication of how an individual’s genetic makeup may affect cardiovascular health, including 24 heart-related conditions.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »